Women Have Been Left Out of Medical Research — and the Consequences Are Still Here

Until 1993, the default research subject in most clinical trials was a seventy-kilogram male. Hormonal cycles were deemed a confounding variable, pregnancy an automatic exclusion, and the female body was treated as a smaller, more complicated version of the male one. That was not a footnote. It was the foundation of modern medicine.

The consequences are not historical curiosities. They show up in emergency rooms today, in prescriptions written yesterday, and in the quiet assumption that a treatment that works for men will work for women too. It often does not.

The consequences of studying only men

When drugs are not tested on female bodies, dosing errors follow. Ambien was prescribed in equal doses to men and women for twenty years before the FDA halved the recommended dose for women, after it became clear that women metabolised the drug differently and were more likely to be involved in driving accidents the next morning. It is not an isolated case. Differences in metabolism, fat distribution, kidney function, and hormonal feedback loops mean that a treatment studied only in men is, at best, a rough guess for women.

Symptoms of heart attack in women — nausea, jaw pain, fatigue — were under-recognised for decades because the classic presentation taught in medical schools was a man's. Autoimmune conditions, which disproportionately affect women, remain underfunded relative to their burden. And the hormonal transitions that define half of adult life — perimenopause, menopause, the post-reproductive decades — were long considered cultural footnotes rather than medical priorities.

Medicine cannot treat what it does not measure. And for centuries, it chose not to measure the female body in full.

What the data gap still means today

More subtly, the exclusion of women from research means that many female-dominant conditions lack clear diagnostic criteria, reliable biomarkers, or evidence-based treatments. Chronic fatigue, endometriosis, migraines, and the mood and cognitive symptoms of perimenopause are still routinely minimised or misattributed to anxiety, stress, or ageing itself.

Even now, when funding for women's health research has improved, it remains a fraction of what is spent on conditions that affect similar numbers of people. The gap is not just historical. It is actively reproduced by funding decisions, editorial choices, and a culture that still treats the female body as an afterthought.

What changes it

Better science starts with better representation. That means enrolling women in clinical trials at all life stages, including menopausal and post-menopausal women who are now the largest growing demographic in many countries. It means disaggregating data by sex rather than collapsing it. It means funding research into female-specific conditions at the same level as comparable male-prevalent ones. And it means training clinicians to recognise that a symptom absent from the textbook may still be real — especially when the textbook was written without women in mind.

The female body is not a variant. It is half the population. The sooner research treats it as the default, not the exception, the sooner medicine catches up with the people it claims to serve.